Protocol development has long produced a document that is reviewed, approved and then interpreted again by every delivery function. ICH M11 introduces a harmonised structure, template and technical specification intended to support electronic exchange of protocol information.
The guidance does not turn every protocol into software. It does establish a clearer basis for treating protocol content as information that can be structured, transferred and reused across systems and organisations.
Meaning is carried through defined content and data fields, not layout alone.
Teams need a governed path from approved content into study requirements and systems.
A common structure improves exchange. It does not replace clinical judgement or quality oversight.
01
M11 is more than a new protocol template.
The final FDA guidance describes persistent variability in protocol structure and content as a source of inefficiency in search, review and assessment. M11 addresses that problem through a common protocol structure supported by a technical specification.
Its design principles include a common set of core content, electronic exchange, content reuse and an open data model. Together, those principles shift attention from how a protocol page looks to how protocol information is represented and understood.
Structured information can retain meaning as it moves. That is the strategic change.
02
The operational impact appears downstream.
A structured protocol is valuable when its meaning can reach the people and systems preparing the study. Eligibility criteria affect recruitment assumptions. Visit schedules affect site capacity and participant burden. Endpoint choices affect data capture, technology and oversight.
If those relationships are rebuilt manually after approval, the protocol may be structured while execution remains fragmented.
03
What sponsors and CROs should prepare now.
Decide which structured elements matter downstream and who owns them after approval.
Keep the evidence, assumptions and authority behind a decision connected to the content it shaped.
Make the consequences for sites, participants, vendors and systems visible before delivery begins.
Structure should make qualified review easier, not obscure who made or approved a decision.
04
What M11 does not claim.
The FDA guidance is nonbinding and allows alternative approaches when they satisfy applicable requirements. It does not prescribe how organisations must develop or maintain every protocol, and using the template or technical specification does not by itself establish trial quality.
Those boundaries matter. A structured protocol is an information foundation, not proof that the right decisions were made or executed well.
05
The Tenvia view.
Tenvia treats the approved protocol as structured study intent. It connects evidence, decisions and downstream consequences so teams can review what a design choice means before execution.
That is aligned with the direction represented by M11, but it is a Tenvia product position rather than a regulatory requirement or endorsement.
Explore Protocol IntelligenceAccessed 3 September 2026
M11 Clinical Electronic Structured Harmonised Protocol, May 2026
Clinical electronic Structured Harmonised Protocol, Step 4, 19 November 2025
Harmonised protocol template, Step 4, 19 November 2025
Open, nonproprietary specification for interoperable electronic exchange